Beyang Therapeutics Funding Round

8/12/2026

Venture Equity

$30,000,000

Series A

The company intends to use the funds to accelerate the technological iteration of its proprietary AI + Molecular Design and Optimization platform (ExCEED), advance key pipeline candidates through clinical and pre-clinical development, and expand its international R&D and business development teams.

Private & Independent

Biopharmaceutical

No. 103 Cailun Rd. 1-3A01
Shanghai, 201203
China

Undisclosed

BEYANG Therapeutics Co., Ltd. is an innovative biopharmaceutical company that employs its proprietary ExCEED platforms to accelerate the process of new drug discovery and development in disease areas of significant unmet medical needs. Founders and management team each has more than 20 years of experience and worked at Pfizer, Merck, Astra Zeneca, Schring Plough and Hengrui previously. They are quite experienced in drug target selection, CADD, AIDD, bioassay screening and optimization, as well as DMPK. Together they have contributed to the development of more than 10 clinical candidate molecules, of which three drugs (Sunitinib/Axitinib/Crizotinib) have been approved by FDA and NMPA.